Evofem Inc. — Patent Portfolio
1 drug with active patents · 11 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict The Evofem Inc. portfolio is moderately vulnerable with an average vulnerability score of 65, and the company faces a significant cliff year in 2035 with 1 drug losing exclusivity, including Solosec.
Portfolio overview The Evofem Inc. portfolio consists of a total of 4 drugs, with 1 of them having patents. The company has a total of 11 US patents, all of which are active. The average vulnerability score of the portfolio is 65, indicating a moderate level of vulnerability. Out of the total patents, 0 are ironclad, while 4 are vulnerable.
Cliff calendar The company faces a significant cliff year in 2035, with 1 drug losing exclusivity. This includes Solosec, which will lose exclusivity on September 4, 2035. Additionally, 4 drugs lose exclusivity in 2035 including Solosec.
Most exposed drugs The top drug facing near-term loss of exclusivity is Solosec, with an earliest active patent expiry date of September 4, 2035, an average vulnerability score of 65, and no annual revenue data available. Solosec has 11 patents and is the only drug in the portfolio with a vulnerability score.
Biologic exclusivity There are no biologics in the Evofem Inc. portfolio.
Strategic implications The company faces a total revenue at risk of $0 in the next 5 years. Considering the upcoming loss of exclusivity for Solosec in 2035, the company may want to consider lifecycle moves such as label extensions or combination filings to maintain revenue.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Solosec (SECNIDAZOLE)
Cliff 2035 · 9y-
US12280037
Vuln 75
2041-12-11
This patent protects a method of treating or preventing trichomoniasis using a therapeutically effective amount of secnidazole or a salt in a microgranule formulation.
-
US11602522
Vuln 70
2035-09-04
This patent protects a method of treating sexually transmitted infections by administering a therapeutically effective amount of secnidazole in a microgranule formulation.
-
US11324721
Vuln 70
2035-09-04
This patent protects the use of secnidazole formulations for treating trichomoniasis in a subject in need of treatment.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 11 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Evofem Inc.'s patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export